Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained

Abstract

Risk-reducing mastectomy (RRM) is often advocated for BRCA1/2 mutation carriers who face a heightened lifetime risk of breast cancer. However, many carrier patients seek alternative risk-reducing measures. In a phase II nonrandomized trial, we previously reported that prophylactic irradiation to the contralateral breast among BRCA carriers undergoing breast-conserving treatment significantly reduced subsequent contralateral breast cancer. Herein, we report the outcome of salvage mastectomy and reconstruction in 11 patients that suffered reoccurrences of breast cancer in either the ipsilateral or contralateral breast or elected to have the procedure for risk reduction during the eight-year follow-up period. Patients’ satisfaction with the procedure and physicians’ assessment of the cosmetic outcome were not inferior for previously irradiated compared to non-irradiated breasts. Although the numbers are small, the results are encouraging and sustain hope in a challenging population. Our findings support continuing research as well as a discussion of risk-reduction alternatives besides mastectomy, including prophylactic breast irradiation, in BRCA1/2 mutation carriers.

Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer

“…Notably, patients' satisfaction and physicians' assessment of the cosmetic outcome were not inferior for previously irradiated compared with nonirradiated breasts. 48…”

“…Notably, patients' satisfaction and physicians' assessment of the cosmetic outcome were not inferior for previously irradiated compared with nonirradiated breasts. 48 Recently, a similar randomized phase II Chinese multicenter clinical trial has been registered (ClinicalTrials.gov identifier: NCT04960839). Estimated enrollment is for 323 carrier patients and planned inauguration date is January 1, 2023.…”